Omega-3 effects in patients with Alzheimer's disease

  • Jaqueline Pereira de Oliveira Centro Universitário Regional do Brasil, Salvador-BA, Brasil
  • Samuel Barbosa Camargo Centro Universitário Regional do Brasil, Salvador-BA, Brasil
  • Gabrielle Novais Manzoli Centro Universitário Regional do Brasil, Salvador-BA, Brasil
  • Francisco Navarro Universidade Federal do Maranhão (UFMA), São Luís-MA, Brasil
  • Ricardo Augusto Leoni de Sousa Centro Universitário Regional do Brasil, Salvador-BA, Brasil
Keywords: Alzheimer's disease, Fatty acids, Omega 3, Dietary supplementation

Abstract

Introduction: Alzheimer's disease is a chronic neurodegenerative disease, and the main type of dementia. Objective: This study aims to present the effects of ω-3 supplementation on Alzheimer's disease. Methodology: A systematic review was made through a PubMed search and as inclusion criterion it was adopted that articles published in the last 5 years and original published studies made with humans would be used. The following descriptors were used to search for original articles in PubMed: Alzheimer's Disease, Ômega-3 Fatty Acids and Dietary Supplementation. At the end, 10 articles were reviewed that met all inclusion criteria. Results: Most studies have shown that ω-3 supplementation decreased the biomarkers of inflammation in patients with Alzheimer's, but the improvement in cognition depended on factors such as the dose administered, the duration of the intervention and at which stage of the intervention. disease began supplementation. Discussion: These results indicate that individuals with Alzhimer's disease have to look after their lifestyle and this includes eating. The type of food ingested will develop the disease faster or avoid its development. ω-3 supplementation could help in most studies to fight Alzheimer's progression although a few studies showed no influence of the usage of ω-3. Conclusion: Supplementation with ω-3 promoted the reduction of oxidative stress, and the expression of pro-inflammatory proteins, increased expression of anti-inflammatory proteins and inhibition or amelioration of cognitive decline.

References

-Andrieu, S.; Guyonet, S.; Coley, N.; Cantet, C.; Bonnefoy, M.; Bordes, S.; Bories, L.; Cufie, M.N.; Dantoine, T.; Dartigues, J.F.; Desclaux, F.; Gabelle, A.; Gasnier, Y.; Pesce, A.; Sudres, K.; Touchon, J.; Robert, P.; Rouaud, O.; Legrand, P.; Payoux, p.; Caubere, J.P.; Weiner, M.; Carrié, I.; Ousset, P.J.; Vellas, B. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. The Lancet Neurology. Vol. 16. Num. 5. 2017. p. 377-389.

-Belkouch, M.; Hachem, M.; Elgot, A.; Lo Van, A.; Picq, M.; Guichardant, M.; Lagarde, M.; Bernoud-Hubac, N. The pleiotropic effects of omega-3 docosahexanoic acid on the hallmarks of Alzheimer’s disease. The Journal off Nutritional Biochemistry. Vol. 38. 2016. p. 1-11.

-Borges, M. C.; Santos, F.M.M.; Telles, R.W.; Correia, M.I.T.D.; Lanna, C.C.D. Ácidos graxos poli-insaturados ômega-3 e lúpus eritematoso sistêmico: o que sabemos? Revista Brasileira de Reumatologia. Vol. 54. Num. 6. 2014. p. 459-466.

-Calder, P, C; Deckelbaum, R, J. Dietary fatty acids in health anddisease: Greatter controversy greater interest. Current Opnion. Vol. 17. Num. 2. 2014. p. 111-115.

-Cardoso, B. R.; Cominetti, C.; Cazzolino, S.M.F. Importance and management of micronutrient deficiencies in patients with Alzheimer’s disease. Published. Clinical Intervetion in Aging. Vol. 8. 2013. p. 531-542.

-Cortes, M.L.; Castro, M.M.C.; Jesus, R.P.; Barros-Neto, J.A.; Kraychete, D.C. Uso de terapêutica com ácidos graxos ômega-3 em pacientes com dor crônica e sintomas ansiosos e depressivos. Revista dor. SP. Vol. 14. Num. 1. 2013. p. 48-51.

-De Felice, F.G.; Ferreira, S.T. Inflammation, Defective Insulin Signaling, and Mitochondrial Dysfunction as Common Molecular Denominators Connecting Type 2 Diabetes to Alzheimer Disease. Vol. 63. Num. 1. 2014. p. 2262-2271.

-Eriksdotter. M.; Vedin, I.; Falahati, F.; Freund-Levi, Y.; Hjorth, E.; Faxén-Irving, G.; Wahlund, L.; Schultzberg, M.; Basun, H.; Cederholm, T.; Palmblad, J. Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study. Journal of Alzheimer’s Desease. Vol. 48. Num. 3. 2015. p. 805-812.

-Falco, A.; Cukierman, D.S.; Hauser-Davis, R.A.; Rey, N.A. Doença de alzheimer: hipóteses etiológicas e perspectivas de tratamento. Revista Química Nova. Vol. 39. Num. 1. 2016. p. 63-80.

-Famenini, S; Rigali, E.A.; Olivera-Perez, H.M.; Dang, J.; Chang, M.T.; Halder, R.; Rao, R.V.; Pellegrini, M.; Porter, V.; Bredesen, D.; Fiala, M. Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognitive impairment patients on ω-3 supplementation. The FASEB Journal. Vol. 31. Num. 1. 2017. p. 148-160.

-Fernandes, J. S. G; Andrade, M. S. Revisão sobre a doença de Alzheimer: diagnóstico, evolução e cuidados. Revista Psicologia, Saúde e Doenças. Vol. 18. Num. 1. 2017. p. 131-140.

-Fiala, M.; Terrando, N.; Dalli, J. Specialized Pro-Resolving Mediators from Omega-3 Fatty Acids Improve Amyloid-βPhagocytosis and Regulate Inflammation in Patients with Minor Cognitive Impairment. Journal of Alzheimer’s disease. Vol. 48. Num. 2. 2015. p. 293-301.

-Fraga, V.G.; Carvalho, M.D.G.; Caramelli, P.; De Sousa, L.P.; Gomes, K.B. Resolution of inflammation, n-3 fatty acid supplementation and Alzheimer disease: A narrative review. Journal of neuroimmonology. Vol. 15. Num. 310. 2017. p. 111-119.

-Freund-Levi.Y.; Vedin, I.; Hjorth, E.; Basun, H.; Faxén-Irving, G.; Schultzberg, M.; Eriksdotter, M.; Palmblad, J.; Vessby, B.; Wahlund, L.; Cederholm, T.; Basu, S. Effects of supplementation with omega-3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Juornal of Alzheimer’s Disease. Vol. 42. Num. 3. 2014a. p. 823-831.

-Freund-Levi.Y.; Vedin, I.; Cederholm, T.; Basun, H.; Faxén-Irving, G.; Eriksdotter, M.; Hjorth, E.; Schultzberg, M.; Vessby, B.; Wahlund, L.; Salen, N. Jr.; Palmblad, J. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation inpatients with Alzheimer's disease: the OmegAD study. Juornal of Internal Medicine. Vol. 275. Num. 4. 2014b. p. 428-436.

-Jernerén, F.; Elshorbagy, A.K.; Oulhaj, A.; Smith, S.M.; Refsum, H.; Smith, A.D. Brain atrophy in cognitively impaired elderly: theimportance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial. The American journal of Clinical Nutrition. Oxford. Vol. 102. Num. 1. 2015. p. 215-221.

-Karimi, M.; Vedin, I.; Freund-Levi. Y.; Basun, H.; Faxén-Irving, G.; Eriksdotter, M.; Wahlund, L.; Schultzberg, M.; Hjorth, E.; Cederholm, T.; Palmblad, J. DHA-rich n-3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the Omegadstudy. The American Juornal of Clinical Nutrition. Vol. 106. Num. 4. 2017. p. 1157-1165.

-Molfino, A.; Gioia, G.; Rossi, F.F.; Muscaritoli, M. The Role for Dietary Omega-3 Fatty Acids Suplementation in older Adults. Journal Nutrients. Vol. 6. Num. 10. 2014. p. 4058-4073.

-Phillips, M.A.; Childs, E.C.; Calder, P.C.; Rogers, P.J. No Effect of Omega-3 Fatty Acid Supplementation on Cognition and Mood in Individuals with Cognitive Impairment and Probable Alzheimer’s Disease: A Randomised Controlled Trial. International Journal of Molecular Sciences. Vol. 16. Num. 10. 2015. p. 24600-24613.

-Shinto, L.; Quinn, J.; Montine, T.; Dodge, H.H.; Woodward, W.; Baldauf-Wagner, S.; Wa chunas, D.; Bumgarner, L.; Bourdette, D.; Silbert, L; Kaye, J. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. Vol. 38. Num. 1. 2014. p. 111-120.

-Talmelli, L. F. S.; Vale, F.A.C.; Gratão, A.C.M.; Kusumota, L.; Rodrigues, R.A.P. Doença de Alzheimer: declínio funcional e estágio da demência. Revista ACTA Paulista de enfermagem. Vol. 26. Num. 3. 2013. p. 219-225.

-Thomas, C.; Thomas, C.J.; Radicliffe, J.; Itsiopoulos, C. Omega-3 Fatty Acids in Early Prevention of Inflammatory Neurodegenerative Disease: A Focus on Alzheimer's Disease. BioMed Research International. 2015. p. 1-13.

-Yassine, H.N.; Rawat, V.; Mack, W.J.; Quinn, J.F.; Yurko-Mauro, K.; Bailen-Hall, E.; Aisen, P.S.; Chui, H.C.; Schneider, L.S. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s disease. Alzheimer's Research & Therapy. Vol. 8. Num. 25. 2016. p. 1-10.

Published
2019-01-19
How to Cite
Oliveira, J. P. de, Camargo, S. B., Manzoli, G. N., Navarro, F., & Sousa, R. A. L. de. (2019). Omega-3 effects in patients with Alzheimer’s disease. Brazilian Journal of Obesity, Nutrition and Weight Loss, 12(76), 1078-1086. Retrieved from https://www.rbone.com.br/index.php/rbone/article/view/855
Issue
Vol. 12 No. 76 (2018): Supplement 2
Section
Scientific Articles - Original

Authors who publish in this journal agree to the following terms:

  • Authors retain the copyright and grant the journal the right of first publication, with work simultaneously licensed under the Creative Commons Attribution License BY-NC which allows the sharing of the work with acknowledgment of the authorship of the work and initial publication in this journal.
  • Authors are authorized to enter into additional contracts separately for non-exclusive distribution of the version of the work published in this journal (eg, publishing in institutional repository or book chapter), with acknowledgment of authorship and initial publication in this journal.
  • Authors are allowed and encouraged to post and distribute their work online (eg, in institutional repositories or on their personal page) at any point before or during the editorial process, as this can bring about productive change as well as increase impact and impact. citation of published work (See The Effect of Free Access).

Most read articles by the same author(s)